top of page

Conversation 1: How can we work together to improve outcomes for people with rare and less common cancers? 


Conversation 1 Panel Chair: Liz Darlison
CEO and Director of Support and Clinical Services, Mesothelioma UK

Liz has enjoyed nearly 40 years of clinical practice at the University Hospitals of Leicester, with the last 23 years of practice spent bridging both respiratory and cancer services.  It was from here Liz established Mesothelioma UK, a national charity for mesothelioma. Currently she is a Consultant Nurse at UHL and is also CEO at Mesothelioma UK.  Liz has Honorary university positions in both Leicester and Sheffield, is very research active, keenly promotes nursing as a career and engages in education and training on many levels.  

In the 2019 Queen Elizabeth’s Birthday honours list, Liz was invited to become a Member of the British Empire (MBE) in recognition of her services to patients and cancer research. 

Dr Max Brodermann

Haematology Registrar at UCLH and Trustee, Cancer52

Max Brodermann is a haematology registrar at University College Hospital and a trustee of Cancer52. Working as a clinical academic, he has a particular interest in leukaemia and is currently researching new, targeted therapies. Max is passionate about education, improving the patient experience, and working towards better outcomes for all those with rare and less common cancers. 

MHB Headshot passport photo_edited.jpg

Nic Puntis

Patient, Chair, GIST Cancer UK, and Trustee, Cancer52

Nic Puntis became Chair of GIST CANCER UK after he was diagnosed with a GIST cancer in 2009. Since then, he has been involved with Cancer52, sharing the same aims of ending the inequality in diagnosis, treatment and mortality for patients with rare or less common cancers. Nic is an experienced director with strong strategic planning and business development skills. 

bottom of page